A- A A+

Does slow release oral morphine have impact on craving and impulsivity in heroin dependent individuals? 

Giustiniani J, Rothen S, Penzenstadler L, Colombo L, Calzada G, Thorens G, Zullino D. 

Int Clin Psychopharmacol. 2022 Jul 14. doi: 10.1097/YIC.0000000000000418. Epub ahead of print. PMID: 35833289.

Abstract

https://journals.lww.com/intclinpsychopharm/Fulltext/9900/Does_slow_release_oral_morphine_have_impact_on.17.aspx

Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use. 

Bertin C, Bezin J, Chenaf C, Delorme J, Kerckhove N, Pariente A, Tournier M, Authier N. 

Front Psychiatry. 2022 Jun 30;13:893590. doi: 10.3389/fpsyt.2022.893590. PMID: 35845444; PMCID: PMC9282723.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282723/

Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol™ (morphine sulphate). 

Lierheimer S, Beck O, Keller T, Monticelli FC, Böttcher M. 

Drug Test Anal. 2021 Jul 11. doi: 10.1002/dta.3127. Epub ahead of print. PMID: 34250761.

Abstract

https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3127

Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. 

Brothers TD, Fraser J, MacAdam E, Morgan B, Webster D. 

Drug Alcohol Rev. 2021 Aug 4. doi: 10.1111/dar.13365. Epub ahead of print. PMID: 34347327.

Abstract

https://onlinelibrary.wiley.com/doi/10.1111/dar.13365

Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine,

Kirsten Lehmann, Silke Kuhn, Cinzia Baschirotto, Britta Jacobsen, Stephan Walcher, Herbert Görne, Markus Backmund, Norbert Scherbaum, Jens Reimer, Uwe Verthein,

Journal of Substance Abuse Treatment, Volume 127, August 2021, 108350, ISSN 0740-5472, doi.org/10.1016/j.jsat.2021.108350.

Abstract

https://www.sciencedirect.com/science/article/abs/pii/S0740547221000763

Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules. 

Keijzer, L. 

Harm Reduct J 17, 48 (2020). doi.org/10.1186/s12954-020-00389-w

Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules. 

Substitutionsbehandlung und Lebensqualität: Methadon vs. retardiertes Morphinsulfat – eine Vergleichsstudie 

Salvatore M. Giacomuzzi, Y. Riemer2, M. Ertl, G. Kemmler, R. Richter, H. Rössler, H. Hinterhuber

Suchtmed 3 (1) 2001 

Diskussion: Unsere Studie konnte keine Vorteile der Morphinsulfat- Substitution gegenüber Methadon bestätigen. Bei Morphinsulfat muss immer noch mit einem typischen Anteil von Nebenwirkungen gerechnet werden, welche sich nicht wesentlich von Methadon unterscheiden. Im Zuge einer Morphinsulfatbehandlung muss eher ein erhöhter Beikonsum in Kauf genommen werden. Auch zeigte Methadon einen positiveren Einfluss auf das psychische und physische Wohlbefinden als Morphinsulfat. 

Substitutionsbehandlung und Lebensqualität: Methadon vs. retardiertes Morphinsulfat – eine Vergleichsstudie

A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. 

Kinzler ER, Pantaleon C, Iverson M, Aigner S. 

Adv Ther. 2019;36(9):2394-2401. doi:10.1007/s12325-019-01022-4

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822839/

Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care

Cinzia Baschirotto, Kirsten Lehmann, Silke Kuhn, Jens Reimer, Uwe Verthein

Journal of Pharmacological Sciences, 2020, Journal of Pharmacological Sciences, Available online 12 June 2020

https://www.sciencedirect.com/science/article/pii/S1347861320300608

Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

Bertin C, Delorme J, Riquelme M, Peyrière H, Brousse G, Eschalier A, Ardid D, Chenaf C, Authier N.

Br J Clin Pharmacol. 2019 Aug 6. doi: 10.1111/bcp.14082. 

https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14082

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report.

Prinsloo G, Ahamad K, Socías ME MD, MSc.

Subst Abus. 2019 Mar 4:1-3. doi: 10.1080/08897077.2019.1576086.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30829174

Slow release oral morphine versus methadone for the treatment of opioid use disorder.

Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Socías ME, Fairbairn N, Wood E.

BMJ Open. 2019 Apr 2;9(4):e025799. doi: 10.1136/bmjopen-2018-025799.

https://bmjopen.bmj.com/content/9/4/e025799.long

Alternative Opioid Agonists in the Treatment of Opioid Dependence: A Systematic Review [Internet].

Mosdøl A, Ding KY, Hov L.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Mar 8.

https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0098799/

USA. Slow-release oral morphine could expand options for treating opioid abuse

Slow-release oral Morphine (SROM) has emerged as a promising candidate for oral opioid agonist therapy. However, more research is needed before it can be incorporated into U.S. treatment guidelines. A commentary from the British Columbia Centre on Substance Use is published in Annals of Internal Medicine. (American College of Physicians, 25.12.2017)

https://medicalxpress.com/news/2017-12-slow-release-oral-morphine-options-opioid.html

Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.

Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, Ruckes C, Reimer J.

Addiction. 2014 Apr;109(4):617-26. doi: 10.1111/add.12440.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226326/

http://www.dgsuchtmedizin.de/newsletter/fruehere-ausgaben/dgs-info-extra-zur-einfuehrung-von-oralem-retardierten-morphin-substitolr-in-der-substitutionsbehandlung/ 

Ob (retardiertes Morphin) eine geeignete Ergänzung für die bisherigen Substitute auf dem deutschen Markt ist, müssen vor allem herstellerneutrale Studien beweisen. (doccheck, 06.09.2016)

http://news.doccheck.com/de/141506/substitutionstherapie-morphin-schult-um/

Morphin in der Substitutionsbehandlung: Verbreitung und Auswirkung auf substitutionsgestützte Behandlungen. VON CARLOS NORDT, CARLO CAFLISCH & MARCUS HERDENER; Forschungsgruppe Substanzstörungen der Psychiatrischen Universitätsklinik Zürich; RESULTATE AUS DER BEGLEITEVALUATION DER METHADONBEHANDLUNGEN IM KANTON ZÜRICH NR. 21, August 2015

http://www.dppp.uzh.ch/dam/jcr:00000000-287c-7592-0000-000072d6e28e/MethiInfo21.pdf

Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Verthein U, Beck T, Haasen C, Reimer J. Eur Addict Res. 2015;21(2):97-104. doi: 10.1159/000368572. Epub 2014 Nov 22.

http://www.karger.com/Article/FullText/368572